Other therapeutic targets under study, at this time, are being directed toward mediators of type 2 inflammation, as well as TSLP, with CSJ117 [100], and IL-33 with itepekimab [101], which are being studied in moderate–severe patients undergoing ICS-LABA therapy, in addition to etokimab (ANB020) and melrilimab (GSK3772847) against IL-33, both in first experimental phase [100], astegolimab [102] and anti ST-2 (ILC2 receptor for IL-33), which can reduce asthma exacerbations in phase 2 trials. This evidence concerns the gene TSLP and asthma.